Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Rabiner, E. A. Articles by Grasby, P. M. Search for Related Content PubMed Citation Articles by Rabiner, E. A. Articles by Grasby, P. M. Antidepressants Other Somatic Therapy PET

Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low

OBJECTIVE: Positron emission tomography (PET) was used to examine whether the dose of pindolol used to augment antidepressant medication achieves a significant occupancy of the serotonin type 1A (5-HT_1A) autoreceptor in depressed patients receiving medication. METHOD: The authors examined eight depressed patients on one of two regimes of pindolol (2.5 mg t.i.d. and 5.0 mg t.i.d.) with PET and [¹¹C]WAY-100635. RESULTS: The 5-mg t.i.d. regime achieved a modest (19%) but significant occupancy of the 5-HT_1A autoreceptor, while the regime used in the vast majority of clinical trials (2.5 mg t.i.d.) did not achieve a significant occupancy. CONCLUSIONS: The dose of pindolol used in clinical trials is suboptimal and may explain the inconsistent results. Therefore, a thorough test of pindolol’s efficacy will necessitate doses higher than those used in present clinical trials.

This article has been cited by other articles:

				M. Wingen, K.P.C. Kuypers, and J.G. Ramaekers Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI J Psychopharmacol, July 1, 2007; 21(5): 477 - 485. [Abstract] [PDF]

				F. E. Lotrich, R. R. Bies, G. S. Smith, and B. G. Pollock Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol, July 1, 2006; 20(4 Suppl): 33 - 40. [Abstract] [PDF]

				P. B Wood, A. S Kablinger, and G. S Caldito Open Trial of Pindolol in the Treatment of Fibromyalgia Ann. Pharmacother., November 1, 2005; 39(11): 1812 - 1816. [Abstract] [Full Text] [PDF]

				C. F. Reynolds III, G. S. Smith, M. A. Dew, B. H. Mulsant, M. D. Miller, M. Schlernitzauer, J. A. Stack, P. R. Houck, and B. G. Pollock Accelerating Symptom-Reduction in Late-Life Depression: A Double-Blind, Randomized, Placebo-Controlled Trial of Sleep Deprivation Am J Geriatr Psychiatry, May 1, 2005; 13(5): 353 - 358. [Abstract] [Full Text] [PDF]

				P. J. Cowen New drugs, old problems: REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION Advan. Psychiatr. Treat., January 1, 2005; 11(1): 19 - 27. [Abstract] [Full Text] [PDF]

				S. Ahmed, P. D. Mozley, and W. Z. Potter Biomarkers in Psychotropic Drug Development Am J Geriatr Psychiatry, December 1, 2002; 10(6): 678 - 686. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us